Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ResMed stock | $256.99

Learn how to easily invest in ResMed stock.

ResMed Inc is a medical instruments & supplies business based in the US. ResMed shares (RMD) are listed on the NYSE and all prices are listed in US Dollars. ResMed employs 7,970 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ResMed

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RMD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ResMed stock price (NYSE: RMD)

Use our graph to track the performance of RMD stocks over time.

ResMed shares at a glance

Information last updated 2021-10-16.
Latest market close$256.99
52-week range$176.42 - $301.34
50-day moving average $276.20
200-day moving average $242.39
Wall St. target price$260.83
PE ratio 78.8549
Dividend yield $1.59 (0.62%)
Earnings per share (TTM) $3.24

Buy ResMed shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ResMed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ResMed price performance over time

Historical closes compared with the close of $256.99 from 2021-10-18

1 week (2021-10-08) 1.22%
1 month (2021-09-17) -10.13%
3 months (2021-07-19) 1.36%
6 months (2021-04-19) 24.96%
1 year (2020-10-19) 43.24%
2 years (2019-10-18) 95.86%
3 years (2018-10-19) 149.55%
5 years (2016-10-19) 298.31%

Is ResMed under- or over-valued?

Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ResMed's P/E ratio

ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 79x. In other words, ResMed shares trade at around 79x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ResMed's PEG ratio

ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.509. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ResMed's EBITDA

ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1 billion.

The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.

ResMed financials

Revenue TTM $3.2 billion
Operating margin TTM 28.7%
Gross profit TTM $1.9 billion
Return on assets TTM 12.31%
Return on equity TTM 17.63%
Profit margin 14.84%
Book value $19.81
Market capitalisation $37.2 billion

TTM: trailing 12 months

Shorting ResMed shares

There are currently 979,769 ResMed shares held short by investors – that's known as ResMed's "short interest". This figure is 10.3% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting ResMed shares can be evaluated.

ResMed's "short interest ratio" (SIR)

ResMed's "short interest ratio" (SIR) is the quantity of ResMed shares currently shorted divided by the average quantity of ResMed shares traded daily (recently around 507652.33160622). ResMed's SIR currently stands at 1.93. In other words for every 100,000 ResMed shares traded daily on the market, roughly 1930 shares are currently held short.

However ResMed's short interest can also be evaluated against the total number of ResMed shares, or, against the total number of tradable ResMed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ResMed's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ResMed shares in existence, roughly 10 shares are currently held short) or 0.0068% of the tradable shares (for every 100,000 tradable ResMed shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ResMed.

Find out more about how you can short ResMed stock.

ResMed's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ResMed.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

ResMed's total ESG risk score

Total ESG risk: 29.05

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ResMed's overall score of 29.05 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like ResMed is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

ResMed's environmental score

Environmental score: 7.42/100

ResMed's environmental score of 7.42 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

ResMed's social score

Social score: 14/100

ResMed's social score of 14 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

ResMed's governance score

Governance score: 12.64/100

ResMed's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ResMed is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

ResMed's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. ResMed scored a 1 out of 5 for controversy – the highest score possible, reflecting that ResMed has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

ResMed Inc was last rated for ESG on: 2019-01-01.

Total ESG score 29.05
Total ESG percentile 50.28
Environmental score 7.42
Environmental score percentile 4
Social score 14
Social score percentile 4
Governance score 12.64
Governance score percentile 4
Level of controversy 1

ResMed share dividends

30%

Dividend payout ratio: 29.83% of net profits

Recently ResMed has paid out, on average, around 29.83% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.66% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about $1.59 per share.

While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.

ResMed's most recent dividend payout was on 22 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2021 (the "ex-dividend date").

Have ResMed's shares ever split?

ResMed's shares were split on a 2:1 basis on 30 August 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.

ResMed share price volatility

Over the last 12 months, ResMed's shares have ranged in value from as little as $176.4158 up to $301.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ResMed's is 0.345. This would suggest that ResMed's shares are less volatile than average (for this exchange).

ResMed overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries.

Frequently asked questions

What percentage of ResMed is owned by insiders or institutions?
Currently 0.784% of ResMed shares are held by insiders and 69.316% by institutions.
How many people work for ResMed?
Latest data suggests 7,970 work at ResMed.
When does the fiscal year end for ResMed?
ResMed's fiscal year ends in June.
Where is ResMed based?
ResMed's address is: 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
What is ResMed's ISIN number?
ResMed's international securities identification number is: US7611521078
What is ResMed's CUSIP number?
ResMed's Committee on Uniform Securities Identification Procedures number is: 761152107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site